CoChat
Sign Up
Cited by 107

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Role of the endothelin axis and its antagonists in the treatment of cancer

Bagnato, A, Loizidou, M, Pflug, BR, Curwen, J, Growcott, J·2011·British Journal of Pharmacology
DOI 10.1111/j.1476-5381.2011.01217.x
Open this paper in CoChat — free account

Abstract

The endothelins (ET) are a group of proteins that act through G‐protein coupled receptors. Endothelin‐1 (ET‐1) was initially identified as a potent vasoconstrictor and dysregulation of the ET axis contributes to pathological processes responsible for cardiovascular disease states. More recently, the ET axis, in particular ET‐1 acting through the endothelin A receptor (ET A), has been implicated in the development of several cancers through activation of pathways involved in cell proliferation, migration, invasion, epithelial‐mesenchymal transition, osteogenesis and angiogenesis. The endothelin B receptor (ET B) may counter tumour progression by promoting apoptosis and clearing ET‐1; however, it has recently been implicated in the development of some tumour types including melanomas and oligodendrogliomas. Here, we review emerging preclinical and clinical data outlining the role of the ET axis in cancer, and its antagonism as an attractive and challenging approach to improve clinical cancer management. Clinical data of ET A antagonists in patients with prostate cancer are encouraging and provide promise for new ET A antagonist‐based treatment strategies. Given the unexpected opportunities to affect pleiotrophic tumorigenic signals by targeting ET A‐mediated pathways in a number of cancers, the evaluation of ET‐targeted therapy in cancer warrants further investigation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1476-5381.2011.01217.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 116

  1. 10.1161/01.HYP.20.1.89 · DOI
  2. 10.1165/ajrcmb.22.4.3795 · DOI
  3. 10.1046/j.1365-2559.2000.00795.x · DOI
  4. 10.1016/j.molbrainres.2005.02.015 · DOI
  5. 10.1158/1078-0432.CCR-08-1085 · DOI
  6. 10.1054/bjoc.2001.2193 · DOI
  7. 10.1186/1479-5876-2-16 · DOI
  8. 10.1016/j.biocel.2008.01.022 · DOI
  9. Bagnato A, 1995, Autocrine actions of endothelin‐1 as a growth factor in human ovarian carcinoma cells, Clin Cancer Res, 1, 1059
  10. Bagnato A, 1999, Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth, Cancer Res, 59, 720
  11. Bagnato A, 2002, Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade, Cancer Res, 62, 6381
  12. 10.1158/0008-5472.CAN-03-2344 · DOI
  13. 10.1677/erc.1.01077 · DOI
  14. 10.1158/0008-5472.CAN-06-3879 · DOI
  15. Battistini B, 2006, Profile of past and current clinical trials involving endothelin receptor antagonists: the novel ‘‐sentan’ class of drug, Exp Biol Med (Maywood), 231, 653
  16. 10.1038/sj.bjc.6603162 · DOI
  17. Berger Y, 2006, Targeting the endothelin axis in human melanoma: combination of endothelin receptor antagonism and alkylating agents, Exp Biol Med (Maywood), 231, 1111
  18. 10.1038/35020115 · DOI
  19. 10.1021/jm9604585 · DOI
  20. 10.1074/jbc.M000142200 · DOI
  21. 10.1038/nm1699 · DOI
  22. 10.1200/JCO.2003.04.176 · DOI
  23. 10.1002/cncr.22996 · DOI
  24. 10.1158/1078-0432.CCR-07-1508 · DOI
  25. 10.1016/j.brainres.2010.04.075 · DOI
  26. Clozel M, 1994, Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist, J Pharmacol Exp Ther, 270, 228, 10.1016/S0022-3565(25)22357-6 · DOI
  27. Curwen J, 2007, The impact of ZD4054, a specific endothelin A receptor antagonist, on tumor blood supply, invasion, and the bone microenvironment, Mol Cancer Ther, 6, abst A272
  28. 10.1124/pr.54.2.219 · DOI
  29. 10.1038/sj.bjc.6601717 · DOI
  30. 10.1042/CS103S302S · DOI
  31. 10.1007/s004280000362 · DOI
  32. 10.1006/pupt.2000.0242 · DOI
  33. 10.1016/S0002-9440(10)64825-0 · DOI
  34. 10.3181/0802-RM-69 · DOI
  35. 10.1172/JCI115915 · DOI
  36. 10.1021/jm00021a021 · DOI
  37. 10.1007/s10120-007-0421-z · DOI
  38. 10.1002/pros.20252 · DOI
  39. 10.1046/j.1440-1681.1999.03014.x · DOI
  40. 10.1002/bjs.5536 · DOI
  41. 10.1158/0008-5472.CAN-03-1069 · DOI
  42. 10.1097/CAD.0b013e328320791c · DOI
  43. 10.1002/cncr.11129 · DOI
  44. 10.1097/01.fjc.0000166308.63808.16 · DOI
  45. 10.1182/blood-2003-10-3559 · DOI
  46. 10.1021/jm00089a028 · DOI
  47. 10.1073/pnas.91.11.4892 · DOI
  48. 10.1016/j.eururo.2008.11.002 · DOI
  49. 10.1111/j.1464-410X.2010.09638.x · DOI
  50. 10.1136/jcp.56.1.52 · DOI
  51. 10.1016/j.pupt.2007.12.005 · DOI
  52. 10.1158/1078-0432.CCR-08-0543 · DOI
  53. 10.1038/ki.1996.56 · DOI
  54. 10.1007/s10637-006-9014-7 · DOI
  55. 10.1186/1476-4598-9-69 · DOI
  56. Kelland NF, 2006, Clinical trials of endothelin antagonists in heart failure: a question of dose?, Exp Biol Med (Maywood), 231, 696
  57. 10.1016/j.jpain.2008.09.009 · DOI
  58. 10.1038/sj.bjp.0707516 · DOI
  59. Knight LJ, 2009, Epigenetic silencing of the endothelin‐B receptor gene in non‐small cell lung cancer, Int J Oncol, 34, 465
  60. 10.1016/S0272-6386(97)90004-4 · DOI
  61. 10.1097/01.fjc.0000166260.35099.d5 · DOI
  62. 10.1387/ijdb.041951rl · DOI
  63. 10.1073/pnas.96.20.11496 · DOI
  64. 10.1038/sj.bjc.6604631 · DOI
  65. 10.2174/1389203043379693 · DOI
  66. 10.1056/NEJM199508103330607 · DOI
  67. 10.1200/jco.2007.25.18_suppl.5102 · DOI
  68. 10.1002/cncr.22043 · DOI
  69. 10.1161/01.RES.72.3.526 · DOI
  70. Morris CD, 2005, ZD4054 reduces endothelin‐1‐induced forearm vasoconstriction in healthy male volunteers, Proc Am Assoc Cancer Res, 46, abst 4187
  71. 10.1038/sj.bjc.6602676 · DOI
  72. 10.1016/j.pharmthera.2005.08.012 · DOI
  73. 10.1097/01.ju.0000096372.07687.86 · DOI
  74. 10.1016/j.eursup.2008.10.004 · DOI
  75. 10.1038/nm0995-944 · DOI
  76. Nelson JB, 1996, Endothelin‐1 production and decreased endothelin B receptor expression in advanced prostate cancer, Cancer Res, 56, 663
  77. Nelson JB, 1997, Methylation of the 5′ CpG island of the endothelin B receptor gene is common in human prostate cancer, Cancer Res, 57, 35
  78. 10.1038/nrc990 · DOI
  79. 10.1002/cncr.23864 · DOI
  80. 10.1172/JCI114601 · DOI
  81. Nussdorfer GG, 1999, Autocrine‐paracrine endothelin system in the physiology and pathology of steroid‐secreting tissues, Pharmacol Rev, 51, 403, 10.1016/S0031-6997(24)01413-3 · DOI
  82. 10.1111/j.1527-3466.2002.tb00082.x · DOI
  83. 10.1074/jbc.273.20.12584 · DOI
  84. 10.1016/S0022-3565(25)12297-0 · DOI
  85. 10.1093/hmg/10.9.903 · DOI
  86. 10.1016/j.phrs.2009.11.003 · DOI
  87. 10.1215/15228517-2008-013 · DOI
  88. Rai A, 2006, Effect of the ETB receptor agonist, IRL‐1620, on paclitaxel plasma pharmacokinetics of breast tumor rats, Exp Biol Med (Maywood), 231, 1120
  89. 10.1016/0006-291X(90)91171-N · DOI
  90. Rosanò L, 2001, Endothelin‐1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells, Cancer Res, 61, 8340
  91. Rosanò L, 2003, Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma, Cancer Res, 63, 2447
  92. 10.1158/1535-7163.MCT-07-0151 · DOI
  93. 10.1158/0008-5472.CAN-07-0883 · DOI
  94. 10.1073/pnas.0807158106 · DOI
  95. 10.1016/S0031-6997(25)06809-7 · DOI
  96. 10.1038/sj.bjp.0702315 · DOI
  97. 10.1016/S0002-9440(10)64791-8 · DOI
  98. 10.2174/092986706776055652 · DOI
  99. 10.1016/j.ejpain.2006.05.007 · DOI
  100. Sekulic A, 2002, Bosentan, a novel endothelin‐A and ‐B receptor antagonist inhibits proliferation of malignant melanoma cells. (Abstract) Meeting of the American Association for Cancer Research
  101. Selting K, 2008, Use of a novel endothelin‐B agonist (SPI‐1620) to alter blood flow to solid tumors for improved chemotherapy delivery in dogs with spontaneously‐occurring tumors, Proc Am Assoc Cancer Res, 49, abst 365
  102. 10.2174/157016107781024082 · DOI
  103. 10.1586/14737140.8.9.1481 · DOI
  104. 10.1158/0008-5472.CAN-08-1879 · DOI
  105. 10.1038/sj.bjp.0704304 · DOI
  106. 10.1016/0006-291X(92)90683-C · DOI
  107. 10.1016/j.bbrc.2009.11.085 · DOI
  108. TrumpDL PayneH MillerK de BonoJS StephensonJ BurrisHAet al. (2010).Safety and efficacy of the specific endothelin A receptor antagonist zibotentan (ZD4054) plus docetaxel in patients with metastatic hormone‐resistant prostate cancer: results of a phase I study. ASCO‐GU Symposium San Francisco CA USA 5–7 Marchabst 193. · DOI
  109. 10.1007/s00210-008-0360-1 · DOI
  110. 10.1111/j.1471-4159.2010.06680.x · DOI
  111. 10.1186/bcr2319 · DOI
  112. 10.1042/CS103S107S · DOI
  113. 10.1016/j.ejphar.2003.08.031 · DOI
  114. 10.1097/01.fjc.0000166309.63808.5f · DOI
  115. 10.1016/j.ejphar.2004.04.016 · DOI
  116. 10.1016/j.lfs.2008.01.008 · DOI

Cited by

See all 107

Metadata

Authors
Bagnato, A., Loizidou, M., Pflug, B., Curwen, J., & Growcott, J.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2011-04-18
Volume
163
Issue
2
Pages
220-233
ISSN
  • 0007-1188
  • 1476-5381
DOI
10.1111/j.1476-5381.2011.01217.x
Cited by
107
References
1
Language
en
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Role of the endothelin axis and its antagonists in the treatment of cancer. https://app.cochat.ai/papers/10.1111/j.1476-5381.2011.01217.x
The paper
Bagnato, A., Loizidou, M., Pflug, B., Curwen, J., & Growcott, J. (2011). Role of the endothelin axis and its antagonists in the treatment of cancer. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2011.01217.x